BUY Dr. Reddy's Laboratories Limited — Kunal Parar, Choice Broking
byKunal Parar, Choice BrokingHorizon: NA (inferred Swing (≤2wk))27 Jul 2026via Zee Business (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·4 Aug · 3d ago
1 advisor has an active short-term BUY call on this stock, issued in the last 14 days
Advisor consensus · adjacent horizon·3 Aug · 4d ago
Dr. Reddy's Laboratories has received U.S. FDA approval for its rituximab biosimilar. Fresenius Kabi will exclusively commercialize the product in the United States. This approval strengthens Dr. Redd
BSE · Company Update·1 Aug · 6d ago
Dr Reddy's Laboratories Ltd received approval for its gonorrhea drug from Thailand, following a US nod, as reported by Business Standard.
BSE · Company Update·28 Jul · 1w ago
Dr Reddy’s Srikakulam facility in Andhra Pradesh gets UFDA Form 483 with 3 observations
NewsCnbc-Tv18·30 Jul · 1w ago
Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·22 Jul · 2w ago
Dr. Reddy's Laboratories will release its Q1FY27 financial results on Wednesday, July 22nd, 2026. An earnings call is scheduled for the same day to discuss financial performance.
NSE · Press Release·13 Jul · 4w ago
Dr. Reddy's Laboratories will announce its Q1FY27 financial results on Wednesday, July 22nd, 2026, followed by an earnings call at 19:30 PM IST.
BSE · Company Update·13 Jul · 4w ago
Dr. Reddy's Laboratories shares fall 7% as most analysts remain bearish after Q1 earnings miss
NewsCnbc-Tv18·23 Jul · 2w ago
Dr. Reddy's Laboratories shares will react to weak Q1 after US-listed ADR falls 10%
NewsCnbc-Tv18·23 Jul · 2w ago
Dr. Reddy's Laboratories shares will react to weak Q1 after US-listed ADR falls 10%
NewsCnbc-Tv18·23 Jul · 2w ago
Dr Reddy's Q1 Results: Semaglutide API provision weighs on profit; margin halves
NewsCnbc-Tv18·22 Jul · 2w ago
1 advisor has an active short-term SELL call on this stock
Advisor consensus · adjacent horizon·9 Jul · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.